Earnings summaries and quarterly performance for Sensus Healthcare.
Executive leadership at Sensus Healthcare.
Board of directors at Sensus Healthcare.
Research analysts who have asked questions during Sensus Healthcare earnings calls.
AV
Anthony Vendetti
Maxim Group
3 questions for SRTS
Also covers: AEMD, AGFY, BHST +19 more
BH
Ben Haynor
Lake Street Capital Markets
2 questions for SRTS
Also covers: APYX, ATEC, BFLY +6 more
BH
Benjamin Haynor
Lake Street Capital Markets
2 questions for SRTS
Also covers: BFLY, EKSO, IDXG +6 more
Eduardo Martinez-Montes
H.C. Wainwright & Co., LLC
2 questions for SRTS
Also covers: ANGO, BLFS, CDXC +8 more
AC
Arslan Cameron
ROTH Capital Partners
1 question for SRTS
Jade Montgomery
H.C. Wainwright
1 question for SRTS
JW
Jason Wittes
Roth Capital Partners, LLC
1 question for SRTS
Also covers: ALUR, ARAY, ATEC +13 more
JP
Jeremy Pearlman
Analyst
1 question for SRTS
Also covers: AEMD, JYNT, LUCD +5 more
YC
Yi Chen
H.C. Wainwright & Co.
1 question for SRTS
Also covers: ANGO, APDN, BLFS +22 more
Recent press releases and 8-K filings for SRTS.
Sensus Healthcare Reports Q3 2025 Results Amidst Significant Reimbursement Code Changes
SRTS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Sensus Healthcare reported Q3 2025 revenues of $6.9 million, a decrease from $8.8 million in Q3 2024, resulting in a net loss of $0.9 million or $0.06 per share, primarily due to a lower number of units sold.
- The company shipped 16 SRT systems in Q3 2025, including three to China, contributing to over 900 systems sold globally since the SRT platform's launch, and saw Fair Deal Agreement treatment volumes increase 20% from the second quarter.
- CMS published first-ever dedicated CPT codes for superficial radiotherapy, which are expected to increase SRT delivery code reimbursement per fraction by over 300% and are anticipated to drive strong demand and sales starting January 1, 2026.
- Sensus Healthcare ended Q3 2025 with a strong balance sheet, holding $24.5 million in cash and no debt, and expects to reach break-even or profitability in Q4 2025 due to pent-up demand following the new reimbursement clarity.
Nov 6, 2025, 9:30 PM
Sensus Healthcare reports Q3 2025 financial results
SRTS
Earnings
Demand Weakening
New Projects/Investments
- Sensus Healthcare reported revenues of $6.9 million for the third quarter of 2025, representing a 21.6% decrease compared to the third quarter of 2024.
- The company recorded a net loss of $0.9 million, or $0.06 per share, for Q3 2025, compared to net income of $1.2 million in the prior-year period.
- Adjusted EBITDA was negative $2.4 million for the third quarter of 2025, a decrease from positive $1.6 million in Q3 2024.
- Sensus Healthcare shipped 16 SRT systems during the quarter and exited the quarter with $24.5 million in cash and no debt as of September 30, 2025.
- The Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer, which management believes will strengthen adoption.
Nov 6, 2025, 9:15 PM
Sensus Healthcare Under Investigation Following Q2 2025 Financial Results
SRTS
Earnings
Legal Proceedings
Demand Weakening
- Bragar Eagel & Squire, P.C. is investigating Sensus Healthcare, Inc. (SRTS) on behalf of its stockholders for potential violations of federal securities laws and/or unlawful business practices.
- This investigation follows Sensus's Q2 2025 financial results, reported on August 7, 2025, where the company reported a GAAP earnings-per-share of -$0.06, missing estimates by $0.09.
- Sensus's revenue for Q2 2025 was $7.3M, representing a 20.7% year-over-year decline and missing estimates by $2M. The decrease was primarily attributed to a lower number of units sold to a large customer.
- Following this news, Sensus's stock price fell $1.89 per share, or 35.32%, to close at $3.46 per share on August 8, 2025.
Aug 31, 2025, 12:13 PM
Sensus Healthcare, Inc. Faces Securities Fraud Investigation
SRTS
Legal Proceedings
Earnings
Demand Weakening
- The Portnoy Law Firm has initiated an investigation into Sensus Healthcare, Inc. (SRTS) for possible securities fraud and may file a class action lawsuit on behalf of investors.
- This investigation follows Sensus's Q2 2025 financial results, reported on August 7, 2025, which showed a GAAP earnings-per-share loss of $0.06 (missing analyst estimates by $0.09) and revenue of $7.3 million (a decline of 20.7% year-over-year and below estimates by $2 million).
- The company attributed the revenue decline primarily to a reduction in units sold to a large customer.
- Following these results, Sensus's stock price declined $1.89 per share, or approximately 35.3%, to close at $3.46 per share on August 8, 2025.
Aug 28, 2025, 7:43 PM
Sensus Healthcare, Inc. Under Investigation by Schall Law Firm
SRTS
Legal Proceedings
Earnings
Demand Weakening
- The Schall Law Firm is investigating Sensus Healthcare, Inc. (SRTS) for potential violations of securities laws, focusing on whether the Company issued false or misleading statements or failed to disclose pertinent information to investors.
- This investigation follows Sensus's Q2 2025 financial results, reported on August 7, 2025, which included a significant miss on earnings per share and a 20.7% year-over-year revenue decrease.
- The Company attributed the revenue decline to lower sales to a large customer.
- Following the news, Sensus shares fell by more than 35.2% the next day.
Aug 24, 2025, 9:34 PM
Sensus Healthcare Receives MDSAP Certification for SRT Product Portfolio
SRTS
Product Launch
Revenue Acceleration/Inflection
- Sensus Healthcare, Inc. (Nasdaq: SRTS) has received Medical Device Single Audit Program (MDSAP) certification for its entire portfolio of superficial radiation therapy (SRT) systems, including the SRT-100®, SRT-100+™, and SRT-100 Vision™.
- This certification is expected to streamline international regulatory efforts and enable faster commercial expansion into key global markets by allowing a single audit to satisfy Quality Management System (QMS) requirements for the U.S. FDA, Health Canada, Brazil’s ANVISA, Japan’s PMDA, and Australia’s TGA.
- The company anticipates that MDSAP certification will reduce approval timelines and associated costs in recognizing jurisdictions, enhancing the ability of Sensus’ international sales and distribution teams to engage hospital systems and specialty clinics.
- Sensus Healthcare’s TransDermal Infusion (TDI) product is also expected to be granted MDSAP certification upon receipt of FDA clearance, which would enhance its commercial prospects outside the U.S..
Jul 24, 2025, 12:00 PM
Sensus Healthcare Inc Reports Q1 2025 Financial Results
SRTS
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Q1 2025 results: Revenue of $8.3 million paired with a net loss of $2.6 million, reflecting a mixed financial performance
- Shipped 21 SRT systems – including a significant order from a large customer – which expanded the installed base to over 880 systems with a target to exceed 900 in Q2
- Reported a 65% increase in FDA treatment volume over the previous quarter, underscoring robust growth in patient treatments
- Strategic investments in sales, marketing, and R&D (including a resubmitted 510(k) application for the TDI and expansion of the Fair Deal Agreement program) are aimed at driving recurring revenue and long-term growth
- Management expects a return to profitability within the next three quarters and for the full year, despite current challenges
May 15, 2025, 8:31 PM
Quarterly earnings call transcripts for Sensus Healthcare.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more